Fintel reports that on June 27, 2025, BMO Capital downgraded their outlook for Verve Therapeutics (NasdaqGS:VERV) from ...

BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is ...